Screening for gynecologic malignancies: A continuing responsibility.
Screening for cervical cancer with the Papanicolaou cervical smear has resulted in a decline in incidence and mortality from cervical cancer. Targeting the unscreened population is the next challenge to reduce the incidence of this disease further. Currently, there are no available screening modalities for endometrial or ovarian cancer. Breakthroughs in molecular genetics may result in screening tests for ovarian cancer.
Runowicz
C D
CD
Division of Gynecologic Oncology, Department of Obstetrics, Gynecology, and Women's Health, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, New York 10461, USA.
Fields
A L
AL
D014408:Biomarkers, Tumor / Q000032:analysis; D016889:Endometrial Neoplasms / Q000175:diagnosis / Q000517:prevention & control; D005260:Female; D005833:Genital Neoplasms, Female / Q000517:prevention & control*; D006801:Humans; D015994:Incidence; D008403:Mass Screening / Q000379:methods; D008967:Molecular Biology; D010051:Ovarian Neoplasms / Q000175:diagnosis / Q000517:prevention & control; D065006:Papanicolaou Test; D012941:Social Responsibility; D015996:Survival Rate; D002583:Uterine Cervical Neoplasms / Q000175:diagnosis / Q000517:prevention & control; D014626:Vaginal Smears / Q000145:classification / Q000379:methods
D014408:Biomarkers, Tumor